Sponsors (17)
The bill strengthens federal oversight, inspections, reporting, and funding for compounding safety—improving drug quality and traceability—but increases fees, compliance and reporting burdens and may reduce availability of customized compounded therapies for some patients while harming smaller compounding providers.
Patients who use compounded drugs (including those with chronic conditions and hospital patients) face lower risk of exposure to contaminated, improperly compounded, or duplicative unregulated formulations because the bill tightens when compounded products are treated as commercially available and requires inspections and greater FDA oversight.
Pharmacies, facilities, and prescribers gain clearer rules and better federal data (including reporting of out‑of‑state compounding volumes) that improve regulatory clarity and help HHS detect large‑scale circumvention of approved drug channels.
HHS fee authority and fee-setting flexibility creates a more predictable funding stream to pay for inspections and compliance activities, which can support sustained oversight and higher product quality at regulated compounding facilities.
Patients who need customized or alternative formulations (e.g., those with allergies, intolerances, or during shortages) may lose access to needed compounded therapies because the bill limits compounding of products that duplicate commercially available drugs and creates thresholds that push facilities to stop compounding certain products.
Small compounding pharmacies and some outsourcing facilities may face significant revenue loss, higher compliance costs, or closures from the 20‑occurrence cap, 100‑event thresholds, increased inspections/registration, and higher fees.
Pharmacies, hospital pharmacies, and prescribers will incur new administrative burdens to document individualized changes, track monthly compounding counts for out‑of‑state patients, and comply with registration/inspection requirements.
Based on analysis of 5 sections of legislative text.
Limits frequent compounding of copies of commercial drugs, adds reporting and inspection rules for high-volume compounders, and lets HHS set a fee to fund oversight.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, and for other purposes.
Introduced December 9, 2025 by Rudy Yakym · Last progress December 9, 2025
Limits how often pharmacies and physicians may compound drugs that are essentially copies of available commercial products, requires annual reporting when such compounding exceeds monthly limits for out-of-state patients, expands inspection and registration rules for high-volume outsourcing facilities, and gives the HHS Secretary authority to set a base establishment fee to fund oversight of compounded drugs. Some provisions take effect on different timelines: reporting applies beginning with calendar year 2025, and certain inspection/registration changes take effect six months after enactment.